%A Chen,Yi %A Chen,Didi %A Wang,Qiang %A Xu,Yajing %A Huang,Xiaowei %A Haglund,Felix %A Su,Huafang %D 2022 %J Frontiers in Immunology %C %F %G English %K pancreatic ductal adenocarcinoma (PADC),Immune characteristics,Immune subtypes,Immune index,Immunotherapy %Q %R 10.3389/fimmu.2021.719105 %W %L %M %P %7 %8 2022-January-17 %9 Original Research %+ Huafang Su,Department of Radiation Oncology, First Affiliated Hospital of Wenzhou Medical University,China,suhuafang@wzhospital.cn %# %! Immunological classification of pancreatic carcinomas %* %< %T Immunological Classification of Pancreatic Carcinomas to Identify Immune Index and Provide a Strategy for Patient Stratification %U https://www.frontiersin.org/articles/10.3389/fimmu.2021.719105 %V 12 %0 JOURNAL ARTICLE %@ 1664-3224 %X BackgroundCancer immunotherapy has produced significant positive clinical effects in a variety of tumor types. However, pancreatic ductal adenocarcinoma (PDAC) is widely considered to be a “cold” cancer with poor immunogenicity. Our aim is to determine the detailed immune features of PDAC to seek new treatment strategies.MethodsThe immune cell abundance of PDAC patients was evaluated with the single-sample gene set enrichment analysis (ssGSEA) using 119 immune gene signatures. Based on these data, patients were classified into different immune subtypes (ISs) according to immune gene signatures. We analyzed their response patterns to immunotherapy in the datasets, then established an immune index to reflect the different degrees of immune infiltration through linear discriminant analysis (LDA). Finally, potential prognostic markers associated with the immune index were identified based on weighted correlation network analysis (WGCNA) that was functionally validated in vitro.ResultsThree ISs were identified in PDAC, of which IS3 had the best prognosis across all three cohorts. The different expressions of immune profiles among the three ISs indicated a distinct responsiveness to immunotherapies in PDAC subtypes. By calculating the immune index, we found that the IS3 represented higher immune infiltration, while IS1 represented lower immune infiltration. Among the investigated signatures, we identified ZNF185, FANCG, and CSTF2 as risk factors associated with immune index that could potentially facilitate diagnosis and could be therapeutic target markers in PDAC patients.ConclusionsOur findings identified immunologic subtypes of PDAC with distinct prognostic implications, which allowed us to establish an immune index to represent the immune infiltration in each subtype. These results show the importance of continuing investigation of immunotherapy and will allow clinical workers to personalized treatment more effectively in PDAC patients.